VTN and neoplasm: Binding of complement proteins to tumour antigens enhances their capture, processing, and presentation to T and B lymphocytes (Arvieux et al, 1988, Carroll, 2004), and with PDT-generated cancer vaccines this property appears critically important for securing ardent immune recognition of targeted tumour and the development of effective antitumour adaptive response (Korbelik and Sun, 2006).